An announcement from Neurotech International Ltd. ( (AU:NTI) ) is now available.
Neurotech International Ltd. reported a significant financial loss for the half-year ending December 2024, with revenues from ordinary activities dropping to zero and a 922% increase in losses compared to the previous year. The substantial loss is largely attributed to increased research and development expenditures, highlighting the company’s ongoing investment in its core focus area despite the financial setback.
More about Neurotech International Ltd.
Neurotech International Ltd. operates in the biotechnology industry, focusing on research and development. The company is primarily engaged in developing innovative solutions for neurological conditions, with a significant emphasis on research and development activities.
YTD Price Performance: -38.33%
Average Trading Volume: 521,980
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$38.56M
For a thorough assessment of NTI stock, go to TipRanks’ Stock Analysis page.